Vertex topped fourth-quarter expectations and reported positive results for its next-generation cystic fibrosis drug. VRTX stock rose.
Vertex’s Next-Gen Cystic Fibrosis Drug Scores Big; Shares Rise On Quarterly Beat
Feb 6, 2024
